Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on October 14, 2021. The filing serves to disclose the identity of a customer previously referenced in reports filed on June 17, 2021, and August 25, 2021.
Key Financial Metrics
The filing references purchase orders with an aggregate value of approximately $29 million. No other financial metrics, including revenue, profit, cash flow, margins, debt, or liquidity, are provided in this specific document.
Material Changes and Disclosures
- Customer Identification: The Company disclosed that the "undisclosed global pharmaceutical customer" from prior filings is Pfizer, Inc.
- Product Application: The proprietary Codexis enzyme product is intended for the manufacture of Pfizer's clinical-stage COVID antiviral therapeutic candidate, PF-07321332.
- Order Status: Delivery dates for the ordered enzyme quantities are subject to various conditions.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary beyond the identification of the customer. A material contingency noted is that delivery dates for the $29 million in orders are conditional.
Investor Verification Points
- Verify the specific conditions attached to the delivery dates for the $29 million in purchase orders.
- Monitor the clinical progress of Pfizer's therapeutic candidate PF-07321332, as it impacts the realization of the enzyme orders.
- Review prior 8-K filings from June and August 2021 for the original terms of the purchase orders.